
Genetic Screen for Antipsychotic Drug ResponseAward last edited on: 11/21/05
Sponsored Program
SBIRAwarding Agency
NIH : NIMHTotal Award Amount
$1,054,000Award Phase
2Solicitation Topic Code
-----Principal Investigator
David PickarCompany Information
Gabriel Pharma LLC (AKA: Potomac Pharma LLC~David Pickar MD )
6500 Seven Locks Road Suite 220
Cabin John, MD 20818
Cabin John, MD 20818
(301) 263-1313 |
cpickar@gabrielpharma.com |
www.gabrielpharma.com |
Location: Single
Congr. District: 08
County: Montgomery
Congr. District: 08
County: Montgomery
Phase I
Contract Number: 1R43MH067351-01Start Date: 00/00/00 Completed: 00/00/00
Phase I year
2002Phase I Amount
$100,000Phase II
Contract Number: 2R44MH067351-02Start Date: 00/00/00 Completed: 00/00/00
Phase II year
2004(last award dollars: 2005)
Phase II Amount
$954,000Thesaurus Terms:
antipsychotic agent, genetic screening, mental disorder chemotherapy, psychopharmacology, schizophrenia, therapy design /development catechol methyltransferase, central nervous system, clozapine, dopamine receptor, dopamine transporter, gene expression, genetic susceptibility, human therapy evaluation, mental health information system, pharmacogenetics, serotonin transporter clinical research, human subject, neuropsychological test, patient oriented research